{"href":"http://player.captivate.fm/services/oembed?url=http%3A%2F%2Fplayer.captivate.fm%2Fepisode%2F17f2b477-d90d-4fb3-a6e1-cdb710a67d22","version":"1.0","provider_name":"Captivate.FM","provider_url":"https://www.captivate.fm","width":600,"height":200,"type":"rich","html":"<iframe style=\"width: 100%; height: 200px;\" title=\"Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 1 \u2014 Inside the Issue of Adverse Event Management\" frameborder=\"0\" scrolling=\"no\" allow=\"clipboard-write\" seamless src=\"http://player.captivate.fm/episode/17f2b477-d90d-4fb3-a6e1-cdb710a67d22\"></iframe>","title":"Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 1 \u2014 Inside the Issue of Adverse Event Management","description":"","thumbnail_width":300,"thumbnail_height":300,"thumbnail_url":"https://artwork.captivate.fm/464a03b3-1b7f-4b39-a2c6-e3de4b1e77b7/8YAjpM6wBeZeb3Gyb3zbR3bE.jpg"}